Abstract
Chimeric antigen receptor (CAR) Tcell therapy has shown limited efficacy against solid tumors in clinical studies in contrast to hematological malignancies. In a paper recently published in Nature, Larson etal. report that CAR Tcell activity against solid tumors depends on cell adhesion mediated by IFNγ signaling, opening the prospect of improving their clinical activity in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
